Copyright
©The Author(s) 2019.
World J Gastroenterol. Sep 7, 2019; 25(33): 4933-4944
Published online Sep 7, 2019. doi: 10.3748/wjg.v25.i33.4933
Published online Sep 7, 2019. doi: 10.3748/wjg.v25.i33.4933
Figure 1 Consort diagram of landmark analysis.
PPI: Proton pump inhibitor.
Figure 2 Survival analysis of PPI users and non-users for the 6-mo landmark period.
PPI: Proton pump inhibitor.
Figure 3 Survival analysis of PPI users and non-users with decompensated liver cirrhosis by cumulative dose exposure in the 6-mo landmark cohort.
PPI: Proton pump inhibitor.
- Citation: De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944
- URL: https://www.wjgnet.com/1007-9327/full/v25/i33/4933.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i33.4933